



A Universal Immunocapture-LC-MS/MS Workflow for Biological Compound Quantitation in Preclinical Studies-Trastuzumab

Increasing sensitivity for better accuracy, robustness, and LLOQ when quantitating complex biological compounds

SCIEX iMethodsTM for Pharma and BioPharma

Key Challenges faced in pre-clinical quantitation of biological compounds using ELISA assay

- Lack of selectivity In discover, generic antibody was typically used in ELISA assay for new biological compound candidate screening which caused lacking of selectivity.
- Substandard data quality Precision and accuracy are compromised at low levels due to interferences.
- Limited linear dynamic range and hook effect –Hook effect is known limitation for ELISA assay which causes false negative or artificial lower results. Only up to three orders of dynamic range for most ELISA assay.
- Limitations on multiplexing assay (MPX): –MPX assay involves potential interactions between multiple different antibodies and antigens in the sample/assay solution.

Key benefits of BiaoBA Kit integrate with QTRAP® 6500 for quantifying pre-clinical samples

- Completed solution for sample preparation Include BioBA reagent kit, step by step sample preparation SOP, and LC-MSMS detail method
- Mass spec selectivity:
 Quantitation antibody using unique peptide sequence with highly reproducibile and accurate quality data even at low end.
- Easy to MPX on Mass spec:

 — By simply adding other biological compound unique peptide MRM transitions, the method can monitor large number of biological analytes in one injection without concerning interferences and compromise data quality.
- Maximized sensitivity QTRAP® 6500 Increased ionization efficiency and heat transfer with the new IonDrive™ Turbo V source and Increased ion sampling efficiency and ruggedness with the new IonDrive™ QJet ion guide results below LOQ 5 ng/mL based on sample volume and assay requirement.

- Large linear dynamic range Measurements tested from 10–50,000 ng/mL are linear with over 4-orders of magnitude (r = 0.996) using 25 uL of plasma volume.
- Wide mass range range of m/z 5 2000 provides versatility for large peptide quantitation




Figure 1. A SCIEX BioBA sample preparation kit. B. Universal immunocapture procedure for human IgG enrichment for preclinical samples

Results and Discussion

Sensitivity and linearity of quantitation

A calibration curve of trastuzumab standards in rat plasma matrix (10 - 50,000 ng/mL) was generated using MultiQuant $^{\text{TM}}$ Software (Figure 1). The tested limit of quantification (LOQ) was 10 ng/mL using 25 uL of rat plasma. Linearity was achieved from 10-50,000 ng/mL with regression coefficient (r) of 0.996.






Figure 2: Example calibration curve for trastuzumab on conventional flow LC




Figure 3: XICs of trastuzumab transitions from standard spike-in rat plasma samples (blank, 5 ng/mL, 10 ng/mL and 100 ng/mL).

 The BioBA solution provided a generic ease of use complete method solution for discovery pre-clinical quantitation analysis with selective and accurate results.

- The mass spectrometer method overcomes the major challenges that ELISA assay encountered. The SCIEX Triple Quad™ and QTRAP® 6500 systems with IonDrive™ technology provide high sensitivity with board linearity range to perform high throughput peptide quantitation
- Trastuzumab peptide properties, stability, and nonspecific adsorption were considered as part of the method development process, resulting in a robust quantitative assay
- Trastuzumab levels were robustly quantified using a conventional high flow LC methodology. In tested low end of quantitation 10ng/mL was found to be accurate and reproducible with over 4 orders of linearity dynamic range.

Table 1: Statistic of trastuzumab quantitation statistics using conventional flow LC

F	No.	Component Na	Actual Conc 10.00	Num, Values 3 of 3	Mean 9.9	Standard D	Percent CV 11.99	Accuracy 98.86	Value #1 9.4	Value #2 9.0	Value #3 11.2
,	1	Anti-HER2.FTI									
	2	Anti-HER2 FTI_	50.00	3 of 3	53.7	4.9	9.03	107.43	56.2	48.1	56.9
	3	Anti-HER2.FTI_	100.00	3 of 3	97.5	6.3	6.48	97.53	102.3	90.4	99.9
	4	Anti-HER2.FTI_	500.00	3 of 3	468.5	17.7	3.78	93.70	454.9	462.0	488.5
Т	5	Anti-HER2.FTI	1000.00	3 of 3	997.3	46.5	4.66	99.73	1050.9	968.6	972.4
	6	Anti-HER2.FTI_	5000.00	3 of 3	5665.4	180.5	3.19	113.31	5738.4	5459.8	5798.1
T.	7	Anti-HER2.FTI	10000.00	3 of 3	10404.2	217.0	2.09	104.04	10427.3	10176.6	10608.7
Т	8	Anti-HER2.FTI_	50000 00	3 of 3	42701.0	994.5	2.33	85.40	41850.2	42458.3	43794.4

For Research Use Only. Not for use in diagnostic procedures.

© 2015 AB Sciex. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license.

500 Old Connecticut Path | Framingham, MA 01701 USA

Publication number: : RUO-MKT-02-2301-A

Conclusion

